Ginkgo Bioworks

Ginkgo is an operating company — a publicly traded horizontal platform for cell engineering — classified in some databases as a private equity firm because of its history incubating and providing platform-as-a-service to ventures. The firm generates revenue and takes equity stakes in partner companies that use its foundry and genetic design infrastructure, blurring the line between platform company and investment vehicle.

Ginkgo structures economics through service fees, milestone payments, and royalties or equity warrants in the companies that use its foundry to develop products. The model means upside is tied to partner commercial success rather than just fee-for-service margins, creating a portfolio of equity-like positions across its Cell Engineering programs.

Motif FoodWorks was a food-tech ingredient company originally incubated inside Ginkgo's foundry before being spun out as an independent entity with external venture backing. Ginkgo used its own platform to design the yeast strains that produced Motif's animal-free heme proteins, retaining equity while demonstrating how its horizontal platform can launch product companies.

Ginkgo's biosecurity arm — dramatically scaled during the COVID-19 pandemic — provides pathogen monitoring, genomic epidemiology, and syndromic surveillance primarily to government clients including the U.S. CDC and agencies in Africa and the Middle East. The infrastructure checks airports, schools, and wastewater systems at population scale.

Jason Kelly serves as CEO, with co-founder Reshma Shetty as COO and Barry Canton as CTO. The founders jointly control a majority of the company's voting power through a dual-class share structure, giving them effective control over major strategic decisions including platform direction, acquisitions, and the pace of capital deployment.

Ginkgo went public in 2021 through a SPAC merger with Soaring Eagle Acquisition Corp at an implied valuation exceeding $15 billion. The firm scaled headcount past 1,200 employees before undergoing significant restructuring in 2023 and 2024 to reduce cash burn, aiming to reach adjusted EBITDA breakeven through program monetization and cost discipline.

Ginkgo does not operate as a traditional fund manager with limited partners. Instead, the public company uses its balance sheet and operating cash flows to fund platform infrastructure and selective incubation, while partners contribute R&D budgets and success-based economics that flow through Ginkgo's operating income.